Antibiotic Usage Reduced Overall Survival by over 70% in Non-small Cell Lung Cancer Patients on Anti-PD-1 Immunotherapy
Antibiotic Usage Reduced Overall Survival by over 70% in Non-small Cell Lung Cancer Patients on Anti-PD-1 Immunotherapy
复制标题
DOI：
10.21873/anticanres.15312
复制
发表时间：
2021-10-01
影响因子：
2
通讯作者：
Tsunoda, Takuya
中科院分区：
文献类型：
--
作者：
Hamada, Kazuyuki;Yoshimura, Kiyoshi;Tsunoda, Takuya
背景/目的：免疫疗法在非小细胞肺癌（NSCLC）患者中的应用越来越多。本研究分析了抗生素使用对接受抗程序性细胞死亡-1 （anti-PD-1）免疫治疗的非小细胞肺癌患者预后的影响。患者和方法：这是一项对69例非小细胞肺癌患者的回顾性研究。69名患者中有18名在抗pd -1治疗开始前21天或开始后21天内接受了抗生素治疗。结果：与未使用抗生素的患者相比，接受抗pd -1抗体治疗的患者的客观缓解率（ORR）、总生存期（OS）和无进展生存期（PFS）显著降低。多因素分析显示，抗pd -1抗体治疗患者的抗生素治疗是PFS的独立阴性预测因素；然而，它不是OS的一个显著的独立预测因素。结论：NSCLC患者在开始抗pd -1治疗前后21天内使用抗生素可显著降低OS和PFS，提示两种治疗不应联合使用。
Background/Aim: There is an increasing use of immunotherapy for non-small cell lung cancer (NSCLC) patients. The present study analysed the effect of antibiotic use on the outcome of NSCLC patients undergoing treatment with anti-programmed cell death-1 (anti-PD-1) immunotherapy. Patients and Methods: This was a retrospective study of 69 NSCLC patients. Eighteen out of 69 patients received antibiotics within 21 days before or within 21 days after start of anti-PD-1 therapy. Results: Patients treated with anti-PD-1 antibodies receiving antibiotics had greatly decreased objective response rate (ORR), overall survival (OS) and progression-free survival (PFS) compared to those who did not use antibiotics. Multivariate analysis showed that antibiotic treatment of patients on anti-PD-1 antibody therapy was an independent negative predictive factor of PFS; however, it was not a significant independent predictive factor of OS. Conclusion: Use of antibiotics within 21 days before and after anti-PD-1 treatment initiation in patients with NSCLC strongly reduced OS and PFS, suggesting the two treatments should not be combined.